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Abstract
Colorectal cancer (CRC) is the third most common malignancy in the world. The risk of death is closely correlated to the
stage of CRC at the time of primary diagnosis. Therefore, there is a compelling need for the identification of blood
biomarkers that can enable early detection of CRC. We used a quantitative proteomic approach with isobaric labeling
(iTRAQ) to examine changes in the plasma proteome of 10 patients with CRC compared to healthy volunteers. Enzyme-
Linked Immunosorbnent Assay (ELISA) and Western blot were used for further validation. In our quantitative proteomics
analysis, we detected 75 human plasma proteins with more than 95% confidence using iTRAQ labeling in conjunction with
microQ-TOF MS. 9 up-regulated and 4 down-regulated proteins were observed in the CRC group. The ORM2 level in plasma
was confirmed to be significantly elevated in patients suffering from CRC compared with the controls. ORM2 expression in
CRC tissues was significantly increased compared with that in corresponding adjacent normal mucous tissues (P,0.001).
ITRAQ together with Q-TOF/MS is a sensitive and reproducible technique of quantitative proteomics. Alteration in
expression of ORM2 suggests that ORM2 could be used as a potential biomarker in the diagnosis of CRC.
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Introduction
In 2009, the American Cancer Society estimated a total of
146,970 new colorectal cancer (CRC) cases and 40% deaths in the
United States. CRC is expected to be the third most common
cancer in America. Since 1975, there has been a notable
improvement in relative CRC 5-year survival rates, as a result of
earlier diagnosis and improving treatments [1]. Sigmoidoscopy
significantly improved the detection rate of CRC. However, its
wide application is still limited due to high costs and inconve-
nience. Thus, specific sera-based tumor markers for early diagnosis
and prognosis are needed.
Plasma/serum markers (e.g. Carcinoembryonic antigen, CEA)
are the most widely used and reliable tumor markers for CRC
because they are easily quantitatively measured, reproducible and
cost effective. Although the current guidelines from the American
Society of Clinical Oncology (ASCO) recommend that CEA levels
should be monitored every 2–3 months for at least 2 years post
diagnosis, there is no clear consensus on the validity of CEA
monitoring [2]. Several studies [3–5] questioned the value of CEA
as a marker of CRC recurrence, especially in patients with normal
preoperative CEA levels. Due to these problems, new biomarkers
are required to improve the early detection and prediction of
recurrence for all kinds of CRC. Different proteomic patterns in
serum present new opportunities to develop novel, highly sensitive
diagnostic tools for early detection of cancers [6].
In the literature, proteomics technologies have been used to study
CRC serum biomarkers. In these studies, proteomics strategies such
as two-dimensional polyacrylamide gel electrophoresis (2-D PAGE),
two-dimensional fluorescence differential in gel electrophoresis (2-D
DIGE), surface-enhanced laser desorption/ionization time of flight
mass spectrometry (SELDI-TOF MS) technology and protein
arrayshavebeenutilized,butnone canprecisely evaluate the level of
up- or down-regulation of the proposed biomarkers. Therefore, it is
difficult to determine their specificities and validity in blinded
studies of the samples [7,8]. To uncover new plasma biomarkers, a
new approach with Isobaric Tags for Relative and Absolute
Quantitation (iTRAQ) has been applied [9]. The stable incorpo-
ration of isotopes into an amine tagging reagent is involved in this
chemicallabelingmethod.Byusingmass spectrometry,proteinscan
be reliably detected and allow comparative quantitation in a
multiplexmanner. The core ofthis methodologyis a multiplexedset
of isobaric reagents that yield amine-derivatized peptides. The
derivatized peptides are indistinguishable in MS, but exhibit intense
low-mass MS/MS signature ions that support quantitation. This
method imparts a mass difference as the basis for quantitation by
measurement of relative peak areas of MS and/or MS/MS mass
spectra. Today, commercially available 4-plex and 8-plex reagents
can be used to label protein samples of interest following trypsin
digestion. Different isobaric tags in this method suggest that in a
single mass spectrometric analysis, up to 4 or 8 different samples,
one of which is a reference, can be simultaneously examined. Given
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the discovery of biomarkers in samples with a wide range of plasma,
body fluids and tissues.
In this study, iTRAQ was coupled with microQ-TOF/MS to
detect differential expressed proteins in plasma from CRC patients
and controls. Among the proteins that were elevated in CRC
plasma, 9 proteins were up-regulated, and 4 were down-regulated.
We discussed their possible functions and verified ORM2 which
may be a potential serological biomarker for (the) CRC patients.
The specific function of this protein has not yet been determined;
however, ORM2 appears to function in modulating the activity of
the immune system during the acute-phase reaction, which maybe
play a potential role in the early development of CRC. Growing
evidence indicates that tumor-associated inflammation can drive
tumor development and progression, while tumor development
and progression could induce inflammation, which may play a
pivotal role in all stages of tumorigenesis. Such inflammatory
molecules can be detected in blood samples from cancaer patients
and may be have a potential role in the early detection of cancer.
In this study, the up-regulation of ORM2 was confirmed by
ELISA in plasma of patients with intestinal system disease.
Results
Identification of candidate biomarkers by microQ-TOF
MS
For microQ-TOF MS protein profiling, plasma samples from
10 CRC patients and 10 individuals in the control group were
collected (2 ml plasma from each individual) and then mixed to
form a sample pool for further test. 100 ml of pooled samples from
each group was immunodepleted of 12 abundant plasma proteins
by immunoaffinity column technique as described in Methods.
Immunodepleted plasma samples were digested with trypsin,
labeled with a unique isobaric tag, combined and simultaneously
analyzed by microQ-TOF MS. CRC group was labeled with
iTRAQ-114 and the healthy control group was labeled with
iTRAQ-117 and then separated by strong cation exchange
chromatography and C18 fractionation. 75 proteins were
identified by microQ-TOF MS with $95% confidence. Among
this group, 13 differentially expressed proteins were selected based
on 1.5-fold over-expression and 1.5-fold under-expression in CRC
patients, compared to the healthy volunteers. Nine proteins of the
13 differentially expressed proteins were up-regulated (Table 1).
Three proteins were found to be significantly elevated in the CRC
group (with ratios from 1.3 to 4.4). Four proteins were down-
regulated in CRC patients, and their expression levels are shown
in Table 2. The statistical variance of tumor versus normal ratios
was within the 95th confidence level (P=0.05).
Measurement of ORM2 in plasma samples
As shown in Fig. 1, plasma ORM2 levels on a log scale in box-
and-whisker plots, median plasma ORM2 concentrations were
significantly higher in CRC compared to the normal colorectum,
hyperplastic polyp, and adenoma (all at P,0.001, respectively).
The plasma ORM2 level was statistically significantly higher in
patients with IBD than in the normal colorectum, colorectal
Table 1. List of the proteins identified up-regulated in the iTRAQ experiments, which indicate the biological processes and
molecular functions of these proteins (P value,0.001).
No. Acc. number
Molecular
Weight Protein name Ratio Biological processes Molecular functions
1 gi|153217289 (+7) 193 kDa complement component 4a 0.6 complement-mediated immunity complement
component
2 gi|117911384 (+4) 44 kDa unnamed protein product 1.3
3 gi|112874 (+14) 48 kDa alpha-1-antichymotrypsin precursor 4.4 lipid metabolism other synthase
4 gi|112877 (+13) 24 kDa alpha-1-acid glycoprotein 1 precursor 1 lipid metabolism synthase
5 gi|119623346 (+10) 57 kDa serpin peptidase inhibitor, clade d 0.7 serine protease inhibitor proteolysis
6 gi|119607823 (+8) 24 kDa orosomucoid 2 4.1 other miscellaneous function protein immunity and defense
7 gi|223961 31 kDa complement c4d 0.8 complement-mediated immunity complement
component
8 gi|3980130 72 kDa unnamed protein product 1
9 gi|15797461 19 kDa unnamed protein product 0.7
doi:10.1371/journal.pone.0031868.t001
Table 2. List of the proteins identified as down regulated from the iTRAQ experiment, indicating is the biological process and
molecular function of these proteins (P,0.001).
No. Acc. number Molecular weight Protein name Ratio (log2) Biological processes Molecular functions
1 gi|119570450 (+17) 23 kDa retinol binding protein 4 20.7 vitamin/cofactor transport other transfer/carrier
protein
2 gi|82492617 67 kDa NADH dehydrogenase subunit 5 20.7 oxidative phosphorylation dehydrogenase
3 gi|114026 (+22) 11 kDa apolipoprotein c-iii precursor 20.7 regulation of lipid, fatty acid
and steroid metabolism
other signaling
molecule
4 gi|34532816 53 kDa unnamed protein product 21.6
doi:10.1371/journal.pone.0031868.t002
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it was statistically significantly higher in patients with IBD than in
CRC (P,0.05).
We assessed whether plasma ORM2 could potentially distin-
guish CRC from benign colorectal diseases. We searched for
correlation (age, gender, TNM stage and histological grade)
between plasma ORM2 levels and CRC patient’s clinicopatho-
logical parameters (Table 3). No significant association was found
between plasma ORM2 concentrations and age, gender, TNM
stage or histological grade.
Measurement of ORM2 in tissue samples
Western blot analysis was used to determine expression of
ORM2 in tissues. When protein expression was measured by
densitometer, the median densitometer value of ORM2 in CRC
cancer tissues was significantly greater than that in corresponding
adjacent normal mucous tissues (P,0.01) (Fig. 2).
Discussion
In recent years, proteomics based biomarker discovery from
serum/plasma has gained momentum. A number of studies have
attempted to use proteomic approaches for the discovery of new
biomarkers for CRC patients [10–14]. Studies by Yong-Sam Kim
[10] revealed 26 candidate biomarkers for CRC by combined 2-
DE and nano-LC-FT-ICR/LTQ MS. Ma et al [11] identified 4
proteins with diagnostic potentials by SELDI investigating the
serum proteome of 62 CRC patients and 31 non-cancer subjects.
However, issues regarding the complexity and dynamic range of
constituent proteins have made it difficult to obtain meaningful
data for interpretation. Both serum and plasma show tremendous
variation in individual protein abundance. LC-MS/MS approach-
es for the analysis of serum/plasma samples afford much better
dynamic range capabilities. In addition, iTRAQ reagents have
gained interests in this field as a useful tool in protein biomarker
discovery. It is the first study to combine iTRAQ with Q-TOF/
MS on plasma specimens of CRC patients to discover potential
biomarkers for CRC. 13 proteins with different expression
patterns in CRC plasma were successfully identified. Among
these 13 proteins, there were several proteins of interest, such as
ORM2, Serpin peptidase inhibitor (clade D), NADH dehydroge-
nase subunit 5 (ND5) and Retinol binding protein 4 (RBP4), which
were selected as beneficial candidates and may be further
investigated. ORM2 (alpha-1-acid glycoprotein), a member of
the acute-phase protein family found to be related to intestinal
system disease [15–18], was selected for further verification and
investigation.
It is known that cancers are accompanied by numerous systemic
physiological and biochemical changes, including glycosylation
which is one of the most important post-translational modifications
of proteins. More and more attentions are being paid on studying
aberrant glycosylation during various pathophysiological states,
including inflammation [19], arthritis [20,21], and cancer [22,23].
During the organization of our data, we found several serological
glycosylated proteins like ORM2, EpCAM changing in levels
during cancer development. In this preliminary research, we
Figure 1. Serum ORM2 levels on a log scale in box-and-whisker
plots. The star (stars) in the figure means a sign for statistical analysis.
One star means P,0.05 and the sign with three stars mean P,0.001.
CRC is statistically different from the normal colorectum, hyperplastic
polyp and adenoma (all at P,0.001, respectively); IBD is statistically
different from normal the colorectum hyperplastic polyp and adenoma
(all at P,0.001, respectively). IBD is statistically different from colorectal
cancer (P,0.05).
doi:10.1371/journal.pone.0031868.g001
Table 3. Clinicopathological characteristics of CRC patients.
Characteristic
No of specimens
(N=180)
Serum ORM2
levels
(ng/mL) P value
Gender
Male 114 233.91
(156.22,379.38)
0.3780
Female 66 200.62
(149.56,339.68)
Age (years)
#Median
(68 years old)
93 219.04
(155.26,378.73)
0.4567
.Median 87 207.57
(149.92,361.37)
TNM stages
Stage I 49 188.86
(113.77,375.23)
0.6211
Stage II 31 208.21
(179.28,376.89)
Stage III 62 232.90
(156.24,363.52)
Stage IV 38 208.43
(165.55,405.93)
Differentiated
Well differentiated 61 235.82
(151.80,434.52)
0.0761
Moderately
differentiated
64 204.14
(150.69,344.08)
Poorly differentiated 55 219.03
(157.21,343.07)
Metastasis
Yes 73 212.55
(157.93,388.21)
0.3774
No 107 208.48
(152.56,346.21)
Values are Median (Inter-quartile range: IQR).
doi:10.1371/journal.pone.0031868.t003
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glycoproteins. Wandall [24] used a novel O-Glycopeptide
microarray to screen seromic profiling of patients with colorectal
cancer.Dai [25] individually imaged the change in glycoproteins
indirectly. These reports encourage another angle to discover
clinical biomarkers for diagnosis and prognosis.
There are several reports of ORM2 in intestinal system disease
and cancers [15–18,26]. ORM2 was considered to be related
to capillary permeability [15]. The function of orosomucoid
was reported to be linked with inflammation and cancer. The
concentration of S-orosomucoid was found to be increased in
patients with Crohn’s disease [16]. Comparing bladder cancer
patients with healthy controls, there were significant differences,
with much more orosomucoid expressed in the cancer group [17].
Similar phenomenon could be also found in patients with
bronchial carcinoma [18]. Using the 2-D DIGE and further
analyzed by MALDI-TOF mass spectrometry in patients with
chronic inflammatory demyelinating polyneuropathy, significant
up-regulation of alpha-1 acid glycoprotein 1 precursor was
identified [26]. Studies have indicated that CEA, similar to alpha
1-acid glycoprotein (orosomucoid) in immunology is postulated as
a biosynthetic precursor of alpha 1-acid glycoprotein [27].
This is the first report of an up-regulation of ORM2 in CRC
plasma. Furthermore, the up-regulation of ORM2 was confirmed
by ELISA in plasma of patients with intestinal system disease. It
was found that ORM2 were significantly increased in patients
suffering from CRC and IBD compared with normal individuals
and patients with hyperplastic polyp and adenoma. ORM 2 is a
key acute phase plasma protein in inflammation, so this protein is
classified as an acute-phase reactant. The specific function of this
protein has not yet been determined, however, ORM2 appears to
function in modulating the activity of the immune system during
the acute-phase reaction. This may serve as a potential mediator of
immune escape in CRC and the detection of ORM2 may be
significant in distinguishing colorectal carcinogenesis from IBD.
To determine the source of ORM2, the CRC tumor tissue and
corresponding adjacent normal mucous tissues were evaluated by
Western blot. The results showed that expression level of ORM2
in CRC cancer tissues was found to be higher than in normal
tissue. Therefore, it is proposed that ORM2 might be involved in
carcinogenesis in patients with CRC cancer.
This study also provides evidence that ORM2 levels in CRC
patients may be useful as a biomarker for diagnosis. Serum CEA
assays are not recommended for screening asymptomatic patients
for cancer. One reason is that the plasma CEA assay is not
diagnostic enough to discriminate between localized malignant
tumors and benign disorders. In our study, the detection of ORM2
using ELISA and Western blot is promising. Plasma ORM2
concentrations were significantly higher in CRC compared to the
normal colorectum, hyperplastic polyp, and adenoma (P,0.001).
Therefore, using ORM2 to monitor potential CRC patients may
be a good way to validate whether ORM2 can be used for
screening asymptomatic patients. However, it is important to
further analyze the diagnostic significance of ORM2 by a large
number of patients in multiple centers before final clinical
application for CRC diagnosis.
Serpin peptidase inhibitor, clade D (heparin cofactor), the
encoded product heparin cofactor which shares homology with
antithrombin III and other members of the alpha 1-antitrypsin
superfamily can rapidly inhibit thrombin in the presence of
heparin. Defects in SERPIND1 are the main cause of heparin
cofactor II deficiency, and heparin cofactor II deficiency can lead
to increased thrombin generation and an a-hypercoagulable state.
This is disadvantageous to the development of cancer. There are
several reports on clade A and E in cancers [28,29], but few on
clade D. Similar protein was also identified as an Alpha-1-
antichymotrypsin precursor. Alpha-1-antichymotrypsin belongs to
the serpin family, is highly expressed in astrocytes and has been
found to play roles in the pathogenesis of classical plaques with
Alzheimer’s diseases. As an acute-phase factor, it can inhibit the
activity of macrophage ectoenzymes and matrix metalloprotei-
nase-9 during skin wound healing [30], but induces TNF-a
production in the study of microglial cell lines [31]. This type of
protease inhibitor has been reported to form complexes with the
kallikrein family such as hK3 (also known as a prostate-specific
antigen), hK2 and hK6, and could be applied in the diagnosis of
prostate cancers [32].
Among the down-regulated proteins, ND5, an essential subunit
component of whole mitochondrial complex I [33,34], plays an
important role in the oxidative phosphorylation process as well as
in carcinogenesis. Some literature indicated that ND5 could
induce hepatomas [35]. Mitochondrial DNA (mtDNA) mutations
have been reported in many kinds of cancers. mtDNA gene defects
may be involved in the pathogenetic mechanisms of fatal
manifestation [36]. Frame-shift mutation in ND5 genes has been
reported in hepatocellular carcinoma, and also in preneoplastic
lesions of the gastrointestinal tract [37]. In this study, we identified
ND5 (67 kDa) as a potential candidate but its precise role in
carcinogenesis still needs further investigation, especially the
mutations.
RBP4, a cytokine secreted by adipose tissue, is a novel adipokine
linked with obesity and insulin resistance of type 2 diabetes. RBP4
also has been demonstrated to be involved, to some extent, in the
development of inflammation and cancer. For example, RBP4
methylation was investigated in esophageal squamous cell
carcinoma [38]. In colorectal carcinoma, the level of RBP
Figure 2. Expressions of ORM2 in CRC and corresponding adjacent normal mucous tissues by Western blot analysis (The sign with
three stars mean P,0.01).
doi:10.1371/journal.pone.0031868.g002
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candidate but further investigation of its function in the
pathogenesis of cancer development is required.
In this preliminary proof-of-principle study, Table 1 and Table 2
list 13 candidate biomarkers for CRC. Most of these have not been
reported as cancer biomarkers, that have shown that iTRAQ
together with Q-TOF/MS is a sensitive, reproducible, robust
technique for identifying statistically significant differences of
protein expression betweenCRC patients and healthy control
plasma samples. From the verification of ORM2, it was found that
ORM2 may be a potential biomarker to distinguish CRC from
IBD. In future studies, larger sample populations will be required
to confirm these potential biomarkers. In our research, ORM2 is
firstly identified as a differently regulated protein in CRC patients
as compared to normal controls with proteomics screening.
However, it requires a lot of bench experiments and clinical tests
before ORM2 can be used as a reliable biomarker. We will
continue our study on ORM2 in two aspects. Firstly, we are
establishing a platform to distinguish and to analyze the
relevancies of distinct levels on glycosyl pattern modifications to
various phases of diseases development based on ORM2. At the
same time, we are also very interested in the function of ORM2 in
the tumour progression owing to it regulates lipid homeostasis and
protein quality control on the endoplasmic reticulum membrane.
Methods
Sample preparation
This study was approved and monitored by the Ethics
Committee of Qilu Hospital, Shangdong University. Plasma
samples for proteomics from 10 CRC patients group and 10
healthy control group were collected (Table 4). For each person,
2 ml blood was obtained by venipuncture and collected in a tube
with EDTA, and the plasma was prepared as recommended by the
HUPO Plasma Proteome Project [40]. There were a total of 419
subjects for ELISA, which were classified into five categories by
standard clinical, radiological endoscopic and histological criteria:
normal control (n=65), hyperplastic polyp (n=59), inflammatory
bowel disease (IBD) (n=62), adenoma (n=53) and CRC
(n=180). For Western blot, a total of 41 sequential patients
diagnosed as CRC were assessed. Tumor specimens and
corresponding adjacent normal mucous tissues (.5 cm from the
margin of the tumor) were collected and stored at 280uC until
use. No patients in this studyreceived any type of therapy, such as
radiation or chemotherapy.
Immunodepletion of high-abundance plasma proteins
Plasma samples from 10 CRC patients and 10 individuals in the
control group were collected (2 ml plasma from each individual)
and then mixed to form a sample pool for further test. Pooled
plasma samples were depleted of the top 12 most abundant
proteins (Albumin, IgG, IgA, IgM, Transferrin, Fibrinogen, a2-
Macroglobulin, a1-Antitrypsin, Haptoglobin, a1-Acid Glycopro-
tein, Apolipoprotein A-I, and Apolipoprotein A-II) using a pre-
packed 2-ml Seppro
TM MIXED12 affinity LC column (GenWay
Biotech, San Diego, CA) on an Agilent 1100 series HPLC system
(Agilent, Palo Alto, CA) according to the recommended
manufacturer’s procedure.
After depletion, the precipitated proteins were dissolved by lysis
buffer (6 M Urea, 4%CHAPS, 1 mM PMSF, 2 mM EDTA).
Protein concentrations were determined by the 2D Quant Kit (GE
healthcare, USA), using albumin as a reference standard (1 mg/ml–
10 mg/ml). Concentrations were measured to 4.83 mg/ml (the CRC
group) and 2.27 mg/ml (the healthy group).
Trypic digeston and iTRAQ reagent labeling
After reduction (10 mM DTT, 100 mM NH4HCO3, 56uC,
45 min) and alkylation (55 mM IAA, 100 mM NH4HCO3,
45 min), each sample (100 mg) was digested with trypsin and
labeled with iTRAQ reagents. These samples were digested in
dissociation buffer (trypsin:protein=1:30) overnight at 37uC.
Peptides were labeled with iTRAQ reagents (114 for the CRC
group, 117 for the healthy group).
Strong cation exchange chromatography and C18
column fractionation
Strong cation exchange chromatography was used to remove
the redundant iTRAQ reagents and interfering substances that
can affect MS analysis. The labeled samples were added to 106
Buffer A (10 mM KH2PO4 in 25% acetonitrile, pH 3.0). High-
resolution cation exchange chromatography was then performed
Table 4. Clinical information of CRC serum specimens.
Sample number
(internal code)
Age
(years)
Gender
(male/female) Differentiation Histological types
TNM/Dukes
State, Stage
Preoperative
CEA (ng/ml)
1 54 female moderate adenocarcinoma T3N0M0/B, II 2.5
2 56 female moderate adenocarcinoma T3N0M0/B, II 3.1
3 45 male moderate adenocarcinoma T3N0M0/B, II 4.6
4 63 male poor adenocarcinoma T4N1M0/C, III 3.7
5 51 male poor adenocarcinoma T3N1M0/C, III 4.2
6 69 female poor adenocarcinoma T3N0M0/B, II 2.9
7 55 female moderate adenocarcinoma T2N0M0/A, I 3.8
8 65 male moderate adenocarcinoma T2N0M0/A, I 4.8
9 47 female poor adenocarcinoma T3N1M0/C, III 5.3
10 33 male poor adenocarcinoma T4NM1/D, IV 5.7
TNM: tumor-node-metastasis classification system.
Pathological type: ulcerative type/protruded type/infiltrating type.
Lymph node metastasis: yes/no.
Depth of invasion: T1/2/3/4.
doi:10.1371/journal.pone.0031868.t004
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eluted with a linear gradient of 0,500 mm KCl (25% v/v ACN,
10 mm KH2PO4, pH 3) over 15 min at a flow rate of 1 ml/min,
with fractions collected at 1-min intervals. Samples were desalted
and further fractionated by using a C18 column on nano HPLC
(PROXEOME, America) followed by MS analysis. The gradient
was 5,40% ACN for 70 min.
Matrix assisted laser desorption ionization-time of flight
(MALDI-TOF)/TOF and microQ-TOF analysis
Machine parameters were set as, ion source 25 kV for positive
matrix factorization (PMF) and 8.0 kV for tandem MS/MS
reflector 26.3 kV for PMF and 29.5 kV for tandem MS/MS, lens
9.5 kV for PMF and 3.5 kV for tandem MS/MS, lift 19.0 kV and
the spectra were acquired in reflection mode in MALDI TOF/
TOF with mass range 700,4000. The peaks with a ratio of S/N
over 5 were automatically labeled by FlexAnalysis (Bruker,
Germany). The PMF peaks with mass intensity of more than
5000 were selected for further MS/MS. The spectra were
acquired in positive ion mode in microQ-TOF with mass range
50,3000, and the dry gas and the nebulizer gas were set as 3 L/
min, and 2 L/min, respectively. The temperature of the spray
chamber was set as 150uC, and the strength of the electric field
was set as 1400 V, the collision energy was set as 35% timing for
low ion mass and 65% timing for high ion mass. Other parameters
were set as default.
Database search
The spectra were processed with microQ-TOF control 3.0
(Bruker, Germany) using default settings, except that the
parameters of transfer funnel RF and collision cell RF were set
as 120 Vpp and 600 Vpp, respectively. The subsequent data
analysis was carried out using the Data Analysis 4.0 Biotools 3.0
(Bruker, Germany), WARP-LC 2.0 (Bruker, Germany), and
Mascot 2.2 (Matrix Science, London, U.K.), respectively. Protein
identification was performed by searching the Swiss-Prot Hu-
man2009–12 database with a precursor ion and fragment mass
tolerance both set as 0.04 Da. Carbamidomethylation of cysteines
was set as fixed modification, and oxidation of methionines,
iTRAQ 8 plex modification of N terminal, K and Y were
considered as variable modifications, respectively. One maximum
mis-cleavage was accepted. The ion score cutoffs were set to 25 for
peptides and to 68 for proteins. Peptide identifications were
accepted if they could be established at greater than 90.0%
probability as specified by the PeptideProphet algorithm. Protein
identifications were accepted if they could be established at greater
than 90.0% probability or contained at least 2 identified peptides.
Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony. For classification, the gene
ontology (GO) symbols of the identified proteins were curated
using the XRef database, and queried against the gene ontology
database using the GoMiner tool (http://discover.nci.nih.gov/
gominer/index.jsp). Prediction of the origin of proteins with
unknown cellular localization was performed using the PSORT II
(http://www.psort.org/).
All protein iTRAQ ratios were transformed to base 2 logarithm
values. In base 2 logarithm space, a 2-fold change in levels was
reported as 1 or -1 for up-regulated and down-regulated changes,
respectively.
Elisa for ORM2
ORM2 levels in plasma were quantified using a commercially
available ELISA kit (Groundwork Biotechnology Diagnosticate,
San Diego, CA), according to the manufacturer’s instructions.
Western blotting for ORM2
Tumor tissues and corresponding adjacent normal mucous
tissues were re-suspended in ice-cold radioimmunoprecipitation
(RIPA) buffer for lysis. A BCA protein assay kit (Beyotime,
Biotechnology, China) was used for protein assay. About 25 mg
protein of samples was loaded, separated on 9.0% Tris-Glycine-
SDS polyacrylamide gels and then electro-transferred onto
polyvinylidene fluoride membranes. After blocking with 5% non-
fat milk, membranes were incubated with ORM2 Ab (1:150,
Yueyan Biological Technology, Shanghai, China) or anti-b-actin
mouse monoclonal antibody (1:500, Santa Cruz Biotechnology,
Santa Cruz, CA) overnight at 4uC. Membranes were further
incubated with polyclonal mouse anti-Goat HRP-conjugated
secondary antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) or polyclonal goat anti-mouse HRP-conjugated secondary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h at
room temperature. Bands were detected using a chemilumines-
cence detection kit (Amersham Pharmacia Biotech, Piscataway,
NJ). The intensity of each band was quantified using ImageJ 1.32
software (National Institutes of Health, Bethesda, MD) after
densitometric scanning of the films.
Statistical analysis
The Kolmogorov–Smirnov test was performed to determine the
distribution of the samples of each group. Data were expressed as
median (inter-quartile range, 1IQR). A non-parametric test
(Kruskal–Wallis test) was applied to analyze differences between
CRC and other groups. P,0.05 was considered as statistically
significant. Statistical analysis was performed with SPSS software
versions 13.0 for windows (SPSS Inc, Chicago, USA).
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